DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Safety Study of Olopatadine Nasal Spray

Information source: Alcon Research
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Perennial Allergic Rhinitis

Intervention: Olopatadine 0.6% nasal spray (Drug); Placebo Nasal Spray (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Alcon Research

Official(s) and/or principal investigator(s):
Margaret Drake, Study Director, Affiliation: Alcon Research


The purpose of this study is to determine whether olopatadine nasal spray is safe and effective when used for up to one year by patients with perennial allergic rhinitis.

Clinical Details

Official title: Safety Study of Olopatadine Nasal Spray

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Mean Response at Day 30 to the Patient-rated Relief Assessment Questionnaire

Secondary outcome: Average Number of Days of Rescue Medication Taken


Minimum age: 12 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Patients with confirmed diagnosis of perennial allergic rhinitis who are 12 years and

older Exclusion Criteria:

- Age 11 years and younger

Locations and Contacts

Waco, Waco, Texas 76712, United States
Additional Information

Starting date: December 2006
Last updated: February 23, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017